PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Both companies show declining cash positions (-7.59% vs GNPX's -42.47%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Below half of GNPX's -42.47%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Above 1.5x GNPX's -30.69%. Michael Burry might investigate for potential short-term asset misclassification or risk.
-8.57%
Below half of GNPX's -41.42%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-5.56%
Below half GNPX's -31.39%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Higher Long-Term Investments Growth compared to GNPX's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half of GNPX's -17.11%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Below half of GNPX's -35.89%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-2.42%
Less than half of GNPX's 18.52%. David Dodd sees a more disciplined AP approach or lower volume.
3.64%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Both GNPX and the company show zero Deferred Revenue (Current) Growth.
-3.64%
Less than half of GNPX's -41.23%. David Dodd sees fewer expansions in other current obligations.
-2.05%
Less than half of GNPX's -24.99%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Less than half of GNPX's -24.99%. David Dodd sees far fewer liability expansions relative to competitor.
3.70%
Less than half of GNPX's -97.50%. David Dodd sees fewer share issuances vs. competitor.
-2.84%
0.5-0.75x GNPX's -4.64%. Martin Whitman is wary of weaker retention or lower profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
Below half GNPX's -39.73%. Michael Burry sees potential underperformance in building shareholder capital.
-8.43%
Below half GNPX's -35.89%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
0.97%
Higher Total Investments Growth compared to GNPX's zero value, indicating better performance.
-4.43%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
7.68%
Less than half of GNPX's 42.47%. David Dodd sees better deleveraging or stronger cash buildup than competitor.